RETRACTED: Clomiphene citrate or anastrozole for ovulation induction in women with polycystic ovary syndrome? A prospective controlled trial

Anastrozole versus clomiphene citrate: which is better for ovulation induction?

“…In contrast with our studies, they found similar ovulation and pregnancy rates, respectively, for CC, 100 mg (68.6%, 7.9%), and anastrozole, 1 mg (67.9%, 10.2%). The notable differences between our studies and those of Badawy et al (11) included [1] the doses of CC used (50 mg vs. 100 mg); [2] the use of anastrozole as a range of single or multiple doses versus a 1-mg multiple dose for 5 days; [3] comparison with an historically matched group (our studies were prospective); and [4] the use of human chorionic gonadotropin (hCG) to trigger ovulation (Badawy et al study). The ovulation rate for CC even with the difference in dosage (50 mg vs. 100 mg) is similar to the rate reported in our studies, but differs for the anastrozole doses we tested (including the 1-mg dose) as the ovulation rates were lower in our studies.…”

“…The rate of multiple gestations with CC is consistent with the incidence reported in the prescribing information (7.98%) (15). Our data corroborate findings of Badawy et al (11) and suggest that anastrozole may be useful in protecting against multiple gestation or the risk of OHSS in certain patients.…”

“…This has also been noted by Badawy et al (11) in a recently published, prospective, comparative trial of anastrozole and CC in 469 cycles (215 patients). In contrast with our studies, they found similar ovulation and pregnancy rates, respectively, for CC, 100 mg (68.6%, 7.9%), and anastrozole, 1 mg (67.9%, 10.2%).…”

“…Azim et al (12) studied the use of AIs for controlled ovarian stimulation in patients with breast cancer and noted a minimal suppressive effect on estradiol when using anastrozole compared with letrozole. Although our studies did not compare anastrozole and letrozole, Badawy et al prospectively compared letrozole versus CC and anastrozole versus CC in two similar trials and compared letrozole versus anastrozole in a third trial (11,13,14). In a 5-day treatment regimen for all medications, 5 mg/day of letrozole was used in 545 cycles (218 patients) versus 100 mg/day of CC (518 cycles, 220 patients); 1 mg/ day of anastrozole was used in 243 cycles (115 patients) versus 100 mg/day of CC (226 cycles, 101 patients); and 2.5 mg/day of letrozole was given in 295 cycles (111 patients) versus 1 mg/day of anastrozole (279 cycles, 109 patients).…”

Aromatase Inhibitors in the Treatment of Unexplained Female Infertility

“…There are clinical scenarios in which AIs may demonstrate an advantage over ovulation induction with CC. AI may be a better choice when a limited number of follicles are required [46]. Due to significantly lower estradiol levels, letrozole may be considered for empirical ovulation induction in infertile patients with estrogendependent neoplasms.…”